Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company's tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.
Instruments, for our purposes, are anything, be they chemical or otherwise, that helps one perform tests and diagnostics, be it in a laboratory setting or not. Many of our companies here are in the business of acquiring, developing, and marketing biomedical, analytical chemistry, semiconductor, or other technical industry equipment. In the medical field we have companies that develop new and better diagnostic equipment such as one that produces a device which allows a doctor to diagnose a fatal abnormal heart rhythm in the span of only a few heartbeats. Another has developed an automated microscope system that helps scientists and others capture digital images of cell samples. Stepping out of the medical and clinical research fields, there is another company listed here that develops electronic and electromechanical instruments that measure the flow of liquids, steam, and gases.
|
| Totals |
Company |
Industry |
| Sales: |
N/A |
$32,130.4 Mil |
| Market Cap: |
$46,978.3 Mil |
$337,675.9 Mil |
| Analysts Recommendation: |
Buy |
Buy |
|
|
| Averages |
Company |
Industry |
 |
| Growth |
| Historic Revenue: |
N/A |
5.2% |
| Estimated Revenue: |
N/A |
11.1% |
| Historic Earnings: |
N/A |
(11.8%) |
| Estimated Earnings: |
N/A |
(3.3%) |
| Stock Price (1 Year): |
5.7% |
20.5% |
| Cash per Share: |
N/A |
(12.4%) |
| Dividend: |
N/A |
N/A |
| Price |
| Trailing PE: |
N/A |
N/A |
| Forward PE: |
46.2 |
33.0 |
| Price-to-Sales: |
N/A |
N/A |
| Price-to-Book: |
N/A |
2.4 |
| Dividend Yield: |
N/A |
N/A |
| Market Cap: |
$46,978.3 Mil |
$8,236.0 Mil |
| Operations |
| Net Margin: |
N/A |
3.7% |
| Gross Margin: |
N/A |
36.3% |
| Return on Equity: |
N/A |
.0 |
| Return on Assets: |
N/A |
.0 |
| Balance Sheet |
| Current Ratio: |
N/A |
2.6 |
| Quick Ratio: |
N/A |
1.6 |
| Cash Ratio: |
N/A |
.6 |
| Debt-to-Equity: |
N/A |
.9 |
| Interest Coverage: |
N/A |
1.7 |
| Technicals |
| Relative-Strength Index: |
45.2 |
N/A |
|
|
|
